Skip Navigation


Carcinogenesis Advance Access originally published online on March 19, 2007
Carcinogenesis 2007 28(7):1408-1417; doi:10.1093/carcin/bgm058
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
28/7/1408    most recent
bgm058v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (12)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Grandal, M. V.
Right arrow Articles by Poulsen, H. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grandal, M. V.
Right arrow Articles by Poulsen, H. S.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

EGFRvIII escapes down-regulation due to impaired internalization and sorting to lysosomes

Michael V. Grandal{dagger}, Roza Zandi1,{dagger}, Mikkel W. Pedersen1, Berthe M. Willumsen2, Bo van Deurs and Hans S. Poulsen1,*

Department of Cellular and Molecular Medicine, The Panum Institute, University of Copenhagen, DK-2200 Copenhagen, Denmark
1 Department of Radiation Biology, Section 6321, Copenhagen University Hospital, DK-2100 Copenhagen, Denmark
2 Department of Molecular Biology, University of Copenhagen, DK-2200 Copenhagen, Denmark

* To whom correspondence should be addressed. Tel: +45 35 45 63 03; Fax: +45 35 45 63 01; Email: skovgaard{at}rh.dk

EGFRvIII is a mutant variant of the epidermal growth factor receptor (EGFR) found exclusively in various cancer types. EGFRvIII lacks a large part of the extracellular domain and is unable to bind ligands; however, the receptor is constitutively phosphorylated and able to activate downstream signaling pathways. Failure to attenuate signaling by receptor down-regulation could be one of the major mechanisms by which EGFRvIII becomes oncogenic. Using a cell system expressing either EGFR or EGFRvIII with no expression of other EGFR family members and with endogenous levels of key degradation proteins, we have investigated the down-regulation of EGFRvIII and compared it to that of EGFR. We show that, in contrast to EGFR, EGFRvIII is inefficiently degraded. EGFRvIII is internalized, but the internalization rate of the mutated receptor is significantly less than that of unstimulated EGFR. Moreover, internalized EGFRvIII is recycled rather than delivered to lysosomes. EGFRvIII binds the ubiquitin ligase c-Cbl via Grb2, whereas binding via phosphorylated tyrosine residue 1045 seems to be limited. Despite c-Cbl binding, the receptor fails to become effectively ubiquitinylated. Thus, our results suggest that the long lifetime of EGFRvIII is caused by inefficient internalization and impaired sorting to lysosomes due to lack of effective ubiquitinylation.

Abbreviations: BSA, bovine serum albumin; CHX, cycloheximide; DMEM, Dulbecco’s modified Eagle’s medium; d.n., dominant negative; EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; HEPES, N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid; HRP, horseradish peroxidase; PBS, phosphate-buffered saline; RT, room temperature; TfR, transferrin receptor


{dagger} These authors contributed equally to this work.

Received October 10, 2006; revised March 2, 2007; accepted March 9, 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Mol. Cell. Biol.Home page
R. Marcotte, L. Zhou, H. Kim, C. D. Roskelly, and W. J. Muller
c-Src Associates with ErbB2 through an Interaction between Catalytic Domains and Confers Enhanced Transforming Potential
Mol. Cell. Biol., November 1, 2009; 29(21): 5858 - 5871.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
D. A. Bax, N. Gaspar, S. E. Little, L. Marshall, L. Perryman, M. Regairaz, M. Viana-Pereira, R. Vuononvirta, S. Y. Sharp, J. S. Reis-Filho, et al.
EGFRvIII Deletion Mutations in Pediatric High-Grade Glioma and Response to Targeted Therapy in Pediatric Glioma Cell Lines
Clin. Cancer Res., September 15, 2009; 15(18): 5753 - 5761.
[Abstract] [Full Text] [PDF]


Home page
Sci SignalHome page
P. H. Huang, A. M. Xu, and F. M. White
Oncogenic EGFR Signaling Networks in Glioma
Sci. Signal., September 8, 2009; 2(87): re6 - re6.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
R. Sulahian, O. Cleaver, and L. J.-s. Huang
Ligand-induced EpoR internalization is mediated by JAK2 and p85 and is impaired by mutations responsible for primary familial and congenital polycythemia
Blood, May 21, 2009; 113(21): 5287 - 5297.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
J. V. Abella and M. Park
Breakdown of endocytosis in the oncogenic activation of receptor tyrosine kinases
Am J Physiol Endocrinol Metab, May 1, 2009; 296(5): E973 - E984.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. D. Chamberlain, T. Chan, J. C. Oberg, A. D. Hawrysh, K. M. James, A. Saxena, J. Xiang, and D. H. Anderson
Disrupted RabGAP Function of the p85 Subunit of Phosphatidylinositol 3-Kinase Results in Cell Transformation
J. Biol. Chem., June 6, 2008; 283(23): 15861 - 15868.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.